Generic Name and Formulations:
Rabies vaccine 2.5Units/mL; grown in human diploid cell cultures (inactivated whole virus); inj.
Sanofi Pasteur, Inc.
Indications for IMOVAX:
Preexposure immunization and postexposure treatment of rabies.
Adults and Children:
Preexposure: 3 inj of 1mL IM each on day 0, 7, and either day 21 or 28. Booster doses: 1mL every 2 yrs (see literature). Postexposure treatment: a 5 dose regimen of 1mL IM given on days 0, 3, 7, 14, 28 or 30 (WHO or ACIP recommendations), and 90 (give 1st dose with rabies immune globulin). If previously immunized against rabies, only 2 doses are given, immediately after exposure, and 3 days later (no rabies immune globulin needed).
Postpone preexposure immunization during acute febrile illness or infection. Immunocompromised: may get suboptimal response (monitor titers). Have epinephrine inj (1:1000) available. Pregnancy (Cat.C).
Immunosuppressants: may get suboptimal response.
Local reactions (pain, erythema, swelling), systemic reactions (nausea, headache, muscle aches, abdominal pain).
Single-dose vial (1mL)—1 (w. syringe and diluent)
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Availability and Affordability of Diabetes Medication Worldwide
- Estradiol, Cortisol, TGF-β1 Involved in Thyroid Immunity During Pregnancy and Postpartum
- Pharmacotherapy Personalization May Optimize Outcomes for Type 2 Diabetes
- Late-Onset Epilepsy Linked to Diabetes
- Examining the Ethical Considerations of Grateful Patient Fundraising
- Muscle Cell Proﬁles Relate to Exercise Response Variation in Type 2 Diabetes